A PHASE I TRIAL OF RADIOIMMUNOTHERAPY (Y-90 CT8466), GEMCITABINE AND HEPATIC

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。目的是确定同时肝动脉输注（HAI）氟去氧嘧啶（FUdR）和静脉注射吉西他滨联合静脉注射钇-90嵌合T84.66的最大耐受剂量（MTD）和相关毒性，用于肝切除或肝转移最大手术减体积（至3cm）后的结直肠癌患者；研究肝转移瘤切除和/或消融后这种辅助治疗的可行性和毒性；评价静脉给药的钇-90和铟-111嵌合物T84.66的生物分布、清除率和代谢；通过连续核显像估计辐射对全身、正常器官和肿瘤的剂量；将治疗前后的蛋白质组学特征与毒副作用和抗肿瘤作用联系起来。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives are to determine the maximum tolerated dose (MTD) and associated toxicities of concurrent hepatic arterial infusion (HAI) fluorodeoxypyrimide (FUdR) and intravenous gemcitabine combined with intravenous Yttrium-90 chimeric T84.66 in colorectal cancer patients after hepatic resection or maximum surgical debulking (to 3cm) of liver metastases; to study the feasibility and toxicities of such adjuvant therapy following resection and/or ablation of liver metastases; to evaluate the biodistribution, clearance and metabolism of Yttrium-90 and Indium-111 chimeric T84.66 administered intravenously; to estimate radiation doses to whole body, normal organs and tumor through serial nuclear imaging; to correlate proteomic profiles pre and post-therapy with toxicities and anti-tumor effects.